Patients with palmoplantar pustulosis have a high disease burden, with younger patients and those with nail involvement having worse quality of life.

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

The Food and Drug Administration has granted Fast Track designation to bempikibart for the treatment of alopecia areata.

Patients with psoriatic arthritis waited longer for diagnosis and were less likely to be prescribed disease-modifying antirheumatic drugs.

Since 1992, research from the ongoing Women's Health Initiative prevented an estimated 126,000 breast cancer cases and produced more than 2400 scientific publications.

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.